News

Personalized predictive model improves risk assessment for coronary artery disease
Coronary artery disease (CAD) is the leading cause of death in the United States. Although effective preventive treatments ...
AHA/ASA Journals2d
Palliative Care and Advanced Cardiovascular Disease in Adults: Not Just End-of-Life Care: A Scientific Statement From the American Heart Association
Cardiovascular disease remains a leading cause of morbidity and mortality in adults despite recent scientific advancements. Although people are living longer lives, there may be an adverse impact on ...
When Alzheimer’s Accelerates: Mayo Clinic Probes Mysterious Rapid Decline
Mayo Clinic researchers are studying why some Alzheimer's patients decline rapidly, aiming to find causes, biomarkers, and ...
Biogen Inc.: Leqembi? (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) wh ...
BioArctic AB: EU approves Leqembi (lecanemab) for treatment of early Alzheimer's disease
The European Commission has today communicated that it has granted BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai's application for Marketing Authorization of ...